CD274 and non-small cell lung carcinoma: Given these studies, integrating ICI in treatment regimens for NSCLC whether neoadjuvant, adjuvant, or advanced-stage can significantly improve PFS and OS outcome, particularly in patients with PD-L1 ≥ 1%, non-squamous histology, and those aged 60–74.